Healthcare commercialization outfit PDI buys RedPath Integrated Pathology just days after rejecting a tentative buyout offer from Digirad.
PDI has bought RedPath Integrated Pathology just days after rejecting a tentative buyout offer from Digirad Corp. (NSDQ:DRAD).
Allergan says it's been approached by a 3rd party with a buyout offer, reportedly Actavis, as it battles a hostile takeover bid by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management.
The debut of Kimberly-Clark spinout Halyard Health on the New York Stock Exchange is generating interest in its infection-prevention business amid global fears about the Ebola outbreak in Africa.
The Centers for Medicare & Medicaid Services approve new reimbursement codes for mammograms using Hologic's 3D breast tomosynthesis technology, sending shares up today on Wall Street.
Here's a look at some of the top legal news stories for medical device companies this week: Smith & Nephew claims another win in patent spat with Arthrex; Biomet inks $6m deal to settle kickback charges; Insurer owes Stryker $8m for Duracon Uni-Knee settlements
Boston Scientific today faces the 1st product liability trials to reach federal court over its Obtryx and Pinnacle pelvic mesh products for female urinary incontinence and pelvic organ prolapse.
Covidien agrees to deal its Stellarex drug-coated balloon to Spectranetics for $30 million is it looks to satisfy U.S. anti-trust regulators ahead of a $43 billion merger with Medtronic.
